Full-Time

Associate Scientist II

Drug Product Analytics

Posted on 11/16/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$104k - $114kAnnually

Mid

San Carlos, CA, USA

This position is onsite in San Carlos, CA.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • BSc or MSc in Pharmaceutics, Chemistry, Biophysics or Biochemistry preferred, with minimum 2 years of relevant experience in the pharmaceutical and/or biotechnology industries.
  • The candidate will have some experience in the analytical characterization of large biomolecular Drug Products.
  • Experience executing bioanalytical components of stability studies.
  • Experience in plate-based assays, immunoassay/ELISA, chromatography methods, and spectrometric methodologies is preferred.
  • Experience in authoring analytical technical documents, including method protocols, SOPs, and reports is preferred.
  • The candidate should have high degrees of both flexibility and organizational skills as well as an eagerness and ability to learn, to effectively navigate Vaxcyte’s multiple projects and timelines.
  • Strong interpersonal skills; ability to communicate effectively both verbally and in written formats are necessary to collaborate effectively with the rest of the Formulation and Drug Product Development team as well as across other teams.
Responsibilities
  • Routine analysis of internal stability samples and reporting of data.
  • Executing non-GxP stability study analysis for thermal, freeze/thaw, and agitation as well as container closure system evaluation for both Drug Substance and adjuvanted vaccine Drug Product materials.
  • Support the Vaxcyte QC team, external analytical, and manufacturing CMOs to enable tech transfer and implementation of processes and analytical methods.
  • Vaxcyte is looking for a flexible individual who would be comfortable working on multiple projects at once, with fluid prioritization to enable aggressive timelines. This position is for a scientific role, which is predominantly lab-based, requiring excellent scientific judgement, independence, rigor, and thorough record-keeping.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA for adult use. Vaxcyte employs advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while eliciting a strong immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial infections on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

23%

1 year growth

61%

2 year growth

132%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from major financial entities like Vanguard and Mutual of America Capital Management indicate strong market confidence in Vaxcyte's potential.
  • The recent $816.5 million raised through stock and warrant sales provides substantial capital for advancing their vaccine pipeline.
  • The appointment of experienced board members like John Furey can provide strategic guidance and enhance corporate governance.

What critics are saying

  • The success of Vaxcyte heavily depends on the clinical and commercial success of its lead product, VAX-24, which is still subject to regulatory approval.
  • The competitive landscape in vaccine development is intense, with numerous established players potentially overshadowing Vaxcyte's market entry.

What makes Vaxcyte unique

  • Vaxcyte leverages its proprietary XpressCF™ cell-free protein synthesis platform, which allows for more efficient and versatile vaccine production compared to traditional cell-based methods.
  • Their focus on broad-spectrum vaccines, such as VAX-24 targeting 24 strains of Streptococcus pneumoniae, sets them apart in the vaccine development landscape.
  • The FDA Breakthrough Therapy designation for VAX-24 underscores the innovative potential and clinical significance of their lead product.

Help us improve and share your feedback! Did you find this helpful?